Introduction
Professor Zhu Xiaodong (朱晓东) is a Professor of Medical Oncology at Fudan University Shanghai Cancer Center (FUSCC) — one of China's most prestigious and highest-volume cancer centers. Professor Zhu is recognized as one of Shanghai's leading lung cancer medical oncologists, with particular expertise in EGFR-targeted therapy, ALK/ROS1 inhibitors, immunotherapy, and comprehensive management of non-small cell lung cancer (NSCLC). His expertise spans the full spectrum of lung cancer systemic treatment, with particular distinction in molecularly targeted therapy for driver mutation-positive NSCLC, immunotherapy combinations, and management of advanced and metastatic lung cancer. International patients with lung cancer consistently regard Professor Zhu as a premier choice at FUSCC for expert lung cancer medical oncology care.
Academic Distinctions & Leadership
- Professor of Medical Oncology, Fudan University Shanghai Cancer Center (FUSCC)
- Member, Chinese Society of Clinical Oncology (CSCO)
- Lung Cancer Committee Member, CSCO
- Member, Chinese Anti-Cancer Association, Lung Cancer Committee
- Editorial Board Member, multiple Chinese oncology journals
- Recipient, multiple Shanghai municipal and national science and technology awards
- Visiting fellow at leading lung cancer centers internationally
Specializations & Expertise
EGFR-Mutated NSCLC
- First-line EGFR TKI therapy (osimertinib, gefitinib, erlotinib, afatinib)
- Osimertinib (Tagrisso) for EGFR-mutated NSCLC
- T790M resistance mutation management
- Third-generation EGFR TKI combinations
- EGFR exon 20 insertion management
- Uncommon EGFR mutation management
- Post-TKI progression strategies
ALK/ROS1/MET-Positive NSCLC
- ALK inhibitors (alectinib, brigatinib, lorlatinib)
- ROS1 inhibitors (crizotinib, entrectinib)
- MET exon 14 skipping mutation management
- MET amplification management
- Resistance mechanism analysis and next-line therapy
Immunotherapy for Lung Cancer
- PD-1/PD-L1 inhibitor monotherapy (pembrolizumab, nivolumab, atezolizumab)
- Immunotherapy + chemotherapy combinations
- Dual immunotherapy combinations
- Immunotherapy for driver mutation-negative NSCLC
- Immunotherapy toxicity management
- Biomarker-guided immunotherapy selection (PD-L1, TMB, MSI)
Other Lung Cancer Subtypes
- Small cell lung cancer (SCLC) chemotherapy and immunotherapy
- KRAS G12C inhibitor therapy (sotorasib, adagrasib)
- BRAF V600E mutation management
- RET fusion management
- NTRK fusion management
- HER2-mutated NSCLC management
Advanced Lung Cancer Management
- Metastatic NSCLC comprehensive management
- Brain metastases management
- Leptomeningeal metastases management
- Oligometastatic disease management
- Palliative care integration
- Clinical trial access for novel agents
Clinical Excellence & Innovation
- Targeted Therapy Expert: Extensive experience with the full spectrum of lung cancer targeted therapies, with particular expertise in EGFR-mutated NSCLC management including resistance mechanisms and post-progression strategies
- Immunotherapy Integration: Expert in biomarker-guided immunotherapy selection and management of immunotherapy toxicities
- Rare Driver Mutations: Experience with rare driver mutations including MET exon 14, RET, NTRK, and HER2 mutations
- Brain Metastases: Comprehensive management of lung cancer brain metastases integrating systemic therapy and radiation oncology
- Clinical Trial Access: Active participation in clinical trials of novel lung cancer agents at FUSCC
Research & Academic Contributions
Professor Zhu is an active researcher with peer-reviewed publications in leading Chinese and international oncology journals. His research focuses on EGFR-targeted therapy outcomes, resistance mechanisms, immunotherapy biomarkers, and novel lung cancer treatments.
Hospital Affiliation
Fudan University Shanghai Cancer Center (FUSCC)
270 Dongan Road, Xuhui District, Shanghai 200032
FUSCC is one of China's most prestigious cancer centers, featuring:
- High-volume lung cancer program
- Comprehensive lung cancer MDT
- Advanced molecular profiling (NGS, EGFR, ALK, PD-L1, TMB)
- Clinical trial access for novel lung cancer agents
- Radiation oncology and thoracic surgery integration
- International patient services with English-speaking coordinators
Why Choose Professor Zhu Xiaodong?
- Lung Cancer Targeted Therapy Expert: Comprehensive expertise in EGFR, ALK, ROS1, MET, and other driver mutations
- Immunotherapy Specialist: Biomarker-guided immunotherapy selection and toxicity management
- Rare Driver Mutations: Experience with uncommon lung cancer driver mutations
- Clinical Trial Access: Novel agent access through FUSCC clinical trials
- Cost-Effective Excellence: Lung cancer treatment costs in Shanghai are typically 60-80% lower than in the US or Europe
- Proven International Track Record: Trusted by patients from around the world
Conditions Treated
- EGFR-mutated NSCLC (all stages)
- ALK-positive NSCLC
- ROS1-positive NSCLC
- MET exon 14 skipping NSCLC
- KRAS G12C NSCLC
- PD-L1 high NSCLC
- Driver mutation-negative NSCLC
- Small cell lung cancer
- Lung cancer with brain metastases
International Patient Services
China Medical Concierge - Shanghai (CMCS) provides comprehensive support for international patients seeking lung cancer medical oncology care with Professor Zhu Xiaodong at FUSCC.
Pre-Arrival Support
- Medical Record Review: Review of your pathology, NGS/molecular profiling, PD-L1, staging CT/PET, and prior treatment history
- Virtual Consultation: Video consultation with Professor Zhu's team
- MDT Review: Arrangement of multidisciplinary lung cancer team review
- Treatment Planning: Personalized systemic treatment plan based on molecular profile
- Cost Transparency: Detailed cost estimate including consultations and treatment
- Visa Assistance: Medical visa guidance and invitation letters
- Travel Arrangements: Flights, airport pickup, and accommodation near the hospital
During Treatment
- Professional Medical Interpretation: Experienced oncology interpreters at all appointments
- Hospital Navigation Support: Registration, payment, and hospital navigation assistance
- 24/7 Support: Round-the-clock assistance for any concerns
Post-Treatment Care
- Report Translation: Complete translation of all pathology and treatment reports
- Treatment Summary: Comprehensive oncology summary for your home oncologist
- Medication Guide: Detailed TKI and oral medication instructions
- Telemedicine Follow-up: Virtual follow-up with Professor Zhu's team
- Long-term Support: Ongoing assistance after returning home
Schedule Your Consultation
If you or a loved one has lung cancer and is seeking expert targeted therapy or immunotherapy, Professor Zhu Xiaodong at Fudan University Shanghai Cancer Center offers world-class lung cancer expertise at a fraction of Western costs.
Contact China Medical Concierge - Shanghai today to request a molecular profiling and staging review, schedule a virtual consultation, and begin planning your journey to Shanghai for expert lung cancer care.
Bridging international patients with Shanghai's finest lung cancer oncologists — because your lung cancer care deserves precision medicine expertise.
0 Kommentare